← Eichor
Study identifier: NCT07492927 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Condition: Clinically Significant Prostate Cancer  ·  Sponsor: Xijing Hospital

PhaseN/A
Planned participants1700
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Jianhua Jiao, MD.  ·  +86 029 84771062  ·  1531769428@qq.com

Always discuss trial participation with your own doctor first.

Locations (10)

Northwestern Memorial HospitalChicago, Illinois, United StatesRecruiting
The First Hospital of Lanzhou UniversityLanzhou, Gansu, ChinaRecruiting
General Hospital of Ningxia Medical UniversityYinchuan, Ningxia, ChinaRecruiting
Qinghai University Affiliated HospitalXining, Qinghai, ChinaRecruiting
Weinan Central HospitalWeinan, Shaanxi, ChinaRecruiting
Shaanxi Provincial People's HospitalXi'an, Shaanxi, ChinaRecruiting
Xijing 986 HospitalXi'an, Shaanxi, ChinaRecruiting
The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, Shaanxi, ChinaRecruiting
Yan'an University Affiliated HospitalYan’an, Shaanxi, ChinaRecruiting
Xijing HospitalXi'an, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07492927